Atara Biotherapeutics Faces Securities Fraud Lawsuit

Shareholders who lost money urged to contact law firm about class action lawsuit

Apr. 13, 2026 at 5:30pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a group of polished metal and glass laboratory equipment arranged elegantly on a clean, monochromatic background, symbolizing the abstract corporate strategy, finance, and regulatory risks facing the biotech industry.A conceptual still life captures the high-stakes regulatory environment facing biotech firms like Atara Biotherapeutics.Los Angeles Today

Glancy Prongay Wolke & Rotter LLP has filed a class action lawsuit against Atara Biotherapeutics, Inc. (NASDAQ: ATRA) on behalf of investors who purchased the company's securities between May 20, 2024 and January 9, 2026. The lawsuit alleges that Atara made materially false and misleading statements about the regulatory prospects of its Epstein-Barr treatment, tabelecleucel, which led to significant stock price declines when the issues were disclosed.

Why it matters

This lawsuit highlights the risks investors face when companies provide overly optimistic information about their drug development pipelines and fail to disclose potential manufacturing and regulatory issues. The outcome of this case could have broader implications for transparency and accountability in the biotech industry.

The details

According to the complaint, Atara failed to disclose that certain manufacturing issues and deficiencies in the ALLELE study made it unlikely the FDA would approve the tabelecleucel Biologics License Application (BLA). The company also allegedly did not reveal that these manufacturing problems subjected Atara to heightened regulatory scrutiny and jeopardized its ongoing clinical trials. When Atara disclosed the FDA's concerns, the company's stock price dropped significantly, injuring investors.

  • On January 16, 2025, Atara disclosed it had received a Complete Response Letter (CRL) from the FDA regarding the tabelecleucel BLA, stating the application would not be approved in its current form.
  • On January 21, 2025, Atara disclosed the FDA had placed a clinical hold on its active Investigational New Drug (IND) applications due to GMP compliance issues identified during the pre-license inspection of a third-party manufacturing facility.
  • On January 12, 2026, Atara disclosed the FDA had issued another CRL regarding the resubmitted tabelecleucel BLA, stating the ALLELE trial was no longer considered adequate to provide evidence of effectiveness for accelerated approval.

The players

Atara Biotherapeutics, Inc.

A biopharmaceutical company focused on developing treatments for serious diseases.

Glancy Prongay Wolke & Rotter LLP

A law firm representing investors in the class action lawsuit against Atara Biotherapeutics.

Got photos? Submit your photos here. ›

What’s next

The deadline for investors to file a lead plaintiff motion in the class action lawsuit is May 22, 2026.

The takeaway

This case highlights the importance of biotech companies being transparent about potential manufacturing and regulatory issues that could impact their drug development pipelines. Investors will be closely watching the outcome of this lawsuit, which could set precedents for greater accountability in the industry.